NCI-H2029細(xì)胞
數(shù)量： 大量
器官來源： 肺
年限： stage E
是否是腫瘤細(xì)胞： 1
物種來源： 人
ATCC Number： CRL-5913?
相關(guān)**： 小細(xì)胞肺癌
生長狀態(tài)： 貼壁生長
運(yùn)輸方式： 凍存運(yùn)輸
Designations: NCI-H2029 [H2029]
Depositors: AF Gazdar, JD Minna
NCI-H2029細(xì)胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens
Morphology:
Source: Organ: lung
Tumor Stage: stage E
Disease: carcinoma; small cell lung cancer
Derived from metastatic site: lymph node
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: NCI-H2029細(xì)胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
DNA Profile (STR): Amelogenin: X
CSF1PO: 10, 11
D13S317: None detected
D16S539: 12
D5S818: 10, 11
D7S820: 9, 11
THO1: 6, 9.3
TPOX: 8
vWA: 15, 20
Age: 69 years
Gender: female
Ethnicity: Caucasian
Comments: The line was established in September 1988.
The patient received prior chemotherapy and radiation therapy.
NCI-H2029細(xì)胞The patient was a smoker.
52 pack years.
Propagation: ATCC complete growth medium: HITES medium supplemented with 5% fetal bovine serum
The base medium for this cell line is ATCC-formulated DMEM:F12 Medium Catalog No.30-2006. To make the complete growth medium,add the following components to the base medium
0.005 mg/ml Insulin
0.01 mg/ml Transferrin
30nM Sodium selenite (final conc.)
10 nM Hydrocortisone (final conc.)
10 nM beta-estradiol (final conc.)
extra 2mM L-glutamine (for final conc. of 4.5 mM)
5% fetal bovine serum (final conc.)
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:5 is recommended
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Centrifuge the cell suspension at 1000 rpm for 10 minutes, resuspend the pellet in fresh medium, aspirate and dispense into new flasks.
Preservation: NCI-H2029細(xì)胞culture medium, 90%; additional fetal bovine serum, 5%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
Recommended serum: ATCC 30-2020
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
